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ABSTRACT 
 
HER2 (human epidermal growth factor receptor-2) and/or estrogen 
receptor (ER) are overexpressed in ~80% of human breast cancers. Although 
modern therapeutics (e.g. Trastuzumab, Tamoxifen) target the HER2 and ER 
receptors, clinical resistance often develops due to activation of downstream 
signaling pathways, including phosphoinositide 3 kinase-AKT/protein kinase B-
mammalian target of rapamycin (PI3K/AKT/mTOR), despite effective upstream 
receptor inhibition. Activation of this pathway increases ribosome biogenesis and 
translation of oncogenic mRNAs, which are controlled by intracellular histone 
deacetylase (HDAC) activity as well. In fact, HDAC inhibitors that have been 
implemented into clinical practice are capable of overcoming resistance to HER2 
and ER targeted therapeutics, in part by inducing the degradation of oncogenic 
transcripts. Given this rationale, we tested the hypothesis that mTOR and HDAC 
inhibitors are more effective in combination than as single agents. This project 
examines the effects of combining a novel investigational inhibitor of both 
complexes MLN0128 that targets mTORC1 and mTORC2, and Trichostatin-A 
(TSA), a potent inhibitor of both class I and class II HDACs, on the viability, 
downstream signaling, and polysome assembly of human breast cancer cell lines 
of various receptor subtypes (HER2-/+ and/or ER -/+), as well as on non-
transformed breast epithelial cells. Our data suggest that combining MLN0128 
and TSA caused synergistic growth inhibition in almost all breast cancer cell lines 
tested. Furthermore, this dual treatment induced greater apoptosis in comparison 
to the single agent treatments in HER2-positive SKBR3 cells, while the viability 
	   vi	  
and apoptosis of non-transformed MCF-10A cells were less affected. Dual 
MLN0128/TSA treatment also decreased AKT-S473 phosphorylation significantly 
more than the single agent treatments in all breast cancer cells, and reduced 
polysome formation in SKBR3 cells, suggesting that the mechanism of action of 
dual MLN0128/TSA treatment involves, in part, the inhibition of ribosome function 
through two separate modes of attack on PI3K/AKT/mTOR signaling.  In 
summary, the synergistic effects of this treatment combination across 
phenotypically diverse breast cancer cell lines warrants further study and clinical 
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INTRODUCTION 
Clinical subtypes in breast cancer 
            Breast cancer is one of the highest leading causes of cancer death in the 
United States. About 12% of women will develop breast cancer over the course 
of their lifetime [1]. It is a heterogeneous disease with variety of subtypes that are 
classified by different histologies, levels of gene expression, disease 
aggressiveness, clinical outcomes, as well as genomic abnormalities [2].  Breast 
cancer can be classified into three clinical subtypes: estrogen receptor (ER+) or 
progesterone receptor (PR+) positive, human epidermal growth factor receptor 2 
positive (HER2+), and triple negative (ER-/PR-/HER2-) disease [2].  ER+ and 
PR+ breast cancer overexpresses either the estrogen or progesterone receptors, 
and is found in 60-80% of breast cancer cases [3]. This type of cancer is more 
common in older patients, and generally has a better prognosis compared with 
the other subtypes. In addition, the ER+/PR+ subtype is associated with more 
differentiated and lower histological grade tumors, which may also play a 
significant role in the prognostic outcomes since lower grade tumors tend to grow 
and spread slower [4].  Furthermore, anti-endocrine therapies have been shown 
to be effective in treating ER+/PR+ breast cancer. For example, the drug 
tamoxifen− clinically used worldwide for more than 3 decades− is effective in 
treating many hormone receptor positive cancers because it is an anti-estrogen 
that blocks the binding of estrogen to ER [5, 6].  
HER2+ breast cancers are found in about 20% of patients and are 
associated with higher mortality rate, along with earlier disease relapse [3]. This 
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more aggressive clinical subtype tends to have a less positive prognosis, partly 
due to the elevated proliferative and metastatic potential induced by HER2 [7]. 
This has led to the development of drugs that specifically target the HER2 
receptor, and aid in the treatment of HER2+ breast cancers. The FDA approved 
Trastuzumab in 1998, which led to the routine use of a clinical assay for HER2 
positivity on all breast cancer cases [3]. Trastuzumab is a monoclonal antibody 
that binds the HER2 receptor and blocks its activation and downstream signaling 
to inhibit HER2-positive breast cancer cell growth and survival [1]. Some HER2+ 
breast cancers acquire resistance to Trastuzumab, which has led to the 
development of multiple approaches to targeting HER2.  For example, in 2007 
the FDA approved the use of Lapatinib [8], a small molecule inhibitor of the 
kinase domain of HER2 (and the related epidermal growth factor receptor 
(EGFR)/HER1 receptor); and in 2012 another HER2 binding antibody, 
Pertuzumab [9] was also FDA approved for the treatment of HER2-positive 
breast cancers. 
The ER-/PR-/HER2-, or triple negative subtype is associated with 
aggressive tumors, and this subtype occurs in about 15% of all breast cancer 
cases [3]. Triple negative breast cancer cells do not express any of the hormone 
receptors (ER, PR) nor HER2, which prevents their treatment by either ER or 
HER2 targeted therapies, leaving systemic chemotherapy as the only treatment 
option [7].  The DNA damage response mechanisms play important roles in 
many triple negative breast cancers, as the tumor suppressors p53, BRCA1, and 
BRCA2 are often mutated in this subtype. Research has shown that p53 is 
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mutated in about 82% of triple negative cancers [3].  Additionally, BRCA1 or 
BRCA2 mutations occur in up to 10% of triple negative cancers, and women with 
either mutation are at a 45-75% lifetime risk of developing breast cancer in their 
lifetimes [10]. Increased mitogenic signaling may also drive the proliferation of 
some triple negative breast cancers. Recent studies carried out by the Cancer 
Genome Atlas indicate that PIC3CA, a gene encoding for an isoform of 
phosphoinositide 3 kinase (PI3K), is mutated in about 9% of triple negative 
breast cancers [11]. The triple negative subtype is also more common in younger 
patients, and in women of African descent. Tumors in these patients are often 
found poorly differentiated and higher grade, which further contributes to their 
poor prognosis [4].  
 
HER2 and the PI3Kinase/Akt/mTOR signaling pathways in breast cancer 
HER2, also known as ErbB2/neu, is a receptor tyrosine kinase (RTK), and 
is one of the four members of the epidermal-like growth factor family of receptors 
(EGFR). The other receptors of the EGFR family are EGFR/HER1, HER3, and 
HER4 [12]. All four of the transmembrane receptors can form homodimers and 
heterodimers, which can be enhanced by ligand binding. HER2 is referred to as 
an “orphan receptor” because unlike the other three it does not directly or singly 
interact with any known ligand. However, it dimerizes with other ligand-binding 
EGFR family members to modulate HER2 tyrosine kinase activity negatively or 
positively depending on the ligand/dimerization partner [13]. Upon dimerization, 
the HER2 receptor undergoes auto-or-trans-phosphorylation. As mentioned 
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previously, the overexpressed and phosphorylated HER2 receptor activates the 
downstream phosphoinositide 3 kinase, protein kinase B (also known as AKT), 
mammalian target of rapamycin (PI3K/AKT/mTOR) pathways, which increase 
cell proliferation and survival [14] (Figure 1). 
PI3Ks are part of a family of lipid kinases that phosphorylate 
phosphatidylinositol at the 3’ hydroxyl group [15, 16]. The dysregulation of the 
PI3K pathway has been found in a variety of cancers [16]. The catalytic subunit 
of PI3K, p110α is involved in regulating cell proliferation, and plays an important 
role in tumorigenesis [17].  Gain-of-function mutations in p110α, specifically in its 
helical and kinase domains, are found in about 30% of tumors, including breast, 
and are associated with increased AKT signaling [17]. Wild type PI3K can be 
activated by RTKs, via adaptor proteins that sequester to its inhibitory subunit 
p85, thereby activating the p110 kinase domain [16].  
Activated p110 phosphorylates PIP2, (phosphatidylinositol 4,5-
biphosphate) thus producing PIP3 (phophatidylnositol-3, 4,5 triphosphate), a lipid 
second messenger [18]. Conversely, PIP3 is negatively regulated via 
dephosphorylation by PTEN (phosphatase and tensin homolog) a tumor 
suppressor protein; however in many cancers, PTEN is inactivated or lost leading 
to increased levels of PIP3 [16]. PIP3, subsequently binds to PDK1 (3-
phosphoinositide dependent protein kinase-1), which phosphorylates and 
activates AKT [16, 19-21].  
AKT is a serine/threonine kinase that controls protein synthesis and cell 
growth by phosphorylating mTOR (mammalian target of rapamycin) [19].  AKT 
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has three isoforms, AKT 1/2/3, as well as at least two phosphorylation sites, 
S473 and T308.  Phosphorylation on both sites increases the kinase activity and 
causes AKT to dissociate from the membrane, allowing it to activate the TORC1 
complex and other downstream substrates [18].  
        mTOR is a serine/threonine kinase that regulates cell growth, proliferation, 
survival, and metabolism [22]. mTOR has two multi-protein complexes, 
mTORC1, and mTORC2. mTORC1 consists of mTOR, mLST8 (G-protein β-
subunit-like protein) and raptor (regulatory associated protein of mTOR). This 
complex is involved in regulating cell growth, proliferation, survival, as well as 
nutrient and energy signals [23].  Furthermore, mTORC1 has been shown to 
phosphorylate p70 S6 kinase (S6K1), and eukaryotic initiation factor 4E- (eIF4E) 
binding protein 1 (4eBP1) [23]. In comparison, mTORC2 consists of mTOR, 
mLST8, and rictor (rapamycin-insensitive companion of mTOR). Unlike 
mTORC1, mTORC2 has been shown to regulate the actin cytoskeleton, and 
phosphorylates AKT on the S473 residue to modulate cell shape, motility, and 
invasive abilities [23].  
In mammals there are two ribosomal S6 kinases, S6K1 and S6K2, whose 
activation is regulated by mTOR [23-25].  A substrate of S6 kinases is the 
ribosomal protein S6, which is also referred to as RPS6. S6 controls cell growth 
by affecting mRNA translation and protein synthesis. mTOR activated S6K1 
promotes translation and protein synthesis by phosphorylating the 40S ribosomal 
protein S6, as well as the translation initiation factor eIF4B [23].   
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4eBP1, is another downstream target of mTOR, that acts as a repressor of 
eIF4E [23]. When 4eBP1 is hypo-phosphorylated, it binds to eIF4E and 
represses cap-dependent translation to prevent eIF4E from binding to eIF4G. 
However, when 4eBP1 is phosphorylated by mTOR, it dissociates from eIF4E, 
which allows for different initiation factors including the 40S ribosomal subunit to 
be positioned at the 5’ end of the mRNA to help start the scanning process of the 
mRNA [23]. Elevated levels of eIF4E have been found in a variety of cancers, 
including breast cancer [26]. Furthermore, overexpression of eIF4E has been 
shown to be tumorigenic by dysregulating translation of oncogenes [24].  Given 
this information, researchers have greatly focused on mTOR inhibition in order to 
identify new and more effective anticancer agents. mTOR inhibitors such as 
rapamycin-related rapalogs (e.g. FDA approved Everolimus and Temsirolimus), 
that inhibit TORC1, have been shown to reduce tumor angiogenesis, and have 
clinical anti-tumor activity [22]. However, they are unable to inhibit TORC2. 
Studies have shown that inhibition of TORC1 alone up-regulates AKT 
phosphorylation which can lead to tumor progression. Specifically, activated S6K 
phosphorylates, and negatively regulates, insulin receptor substrate 1 (IRS-1), 
ultimately leading to decreased PI3K and AKT activity. Consequently, inhibition 
of TORC1 causes reduced S6K activity, and an increase AKT. However, 
inhibition of TORC2 decreases AKT activity. Thus, inhibiting both mTOR 
complexes could prevent activation of that feedback loop and result in improved 
therapeutic effects [23].   
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Mammalian target of rapamycin inhibitors 
Intellikine Inc. (recently acquired by Takeda/Millennium Pharmaceuticals) 
developed the selective TORC1/2 ATP site inhibitor MLN0128 (previously known 
as INK128). Unlike rapamycin and rapalogs that allosterically inhibit TORC1 and 
only weakly inhibit p4eBP1 levels, MLN0128 is able to decrease the 
phosphorylation of S6, and inhibit p4eBP1 levels [27-29]. MLN0128 also 
decreases AKT activity since it inhibits TORC2 as well (Figure 1). MLN0128 has 
been shown to inhibit the proliferation of various subtypes of breast cancer cell 
lines with high potency and to potently inhibit growth in human breast cancer 
xenograft models [29]. Additional research demonstrated that MLN0128 can 
suppress the progression of leukemia, and may have therapeutic effects in 
treating B-cell acute lymphoblastic leukemia [30]. 
 
Histone Deacetylases (HDACs) and their inhibition 
Aside from the mutations in the PI3K/AKT/mTOR pathway, there are 
epigenetic mechanisms that commonly contribute to the development of breast 
and other cancers.  Posttranslational modifications such as acetylation and 
methylation affect gene expression, and may contribute to cancer development 
[31]. Histone deacetylases (HDACs) remove acetyl groups from histones and 
various other non-histone proteins to modulate gene expression [31, 32]. For 
genes like the tumor suppressor p21, an increase in HDAC activity can repress 
its transcription. High expression of HDACs has been documented in many 
different cancers implicating its importance in the carcinogenesis process [32]. 
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Furthermore, a global pattern of histone hypoacetylation has been associated 
with malignant progression of breast cancer [33]. There are three classes of 
mammalian HDACs. Class I includes HDAC1, HDAC2, HDAC3, and HDAC8. 
This class of HDACs are mainly localized in the nucleus [34].  Class II consists of 
HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10. This class of HDACs 
can move between the nucleus and the cytoplasm [34]. Class III 
HDACs− structurally unrelated to the class I or II HDACs− are composed of a 
family of NAD-dependent sirtuins (SIRs).  The SIRs are unaffected by all of the 
class I or II HDAC inhibitors developed to date [34]. It is also interesting to note 
that higher expressions of HDAC4, HDAC8, and HDAC9 have been found in 
tumor tissues in comparison to normal tissues [34].  
Better understanding of HDACs and their role in tumorigenesis has fueled 
the development of HDAC inhibitors (HDACi’s) as a new type of cancer 
therapeutic [34]. HDAC inhibitors prevent HDAC’s from removing acetyl groups 
from histones and non-histone proteins and, therefore, can alter gene expression 
and reverse the diverse tumorigenic effects of increased HDAC activity [34]. 
While HDAC inhibitors have been shown to inhibit angiogenesis and metastasis 
in pre-clinical models, less is known about the mechanism of how they kill tumor 
cells while sparing normal cells [31]. 
The currently available HDACi’s− referred to as pan-HDACi− inhibit both 
class I and class II HDACs. In 2006, the first pan-HDACi inhibitor, Vorinostat was 
clinically approved for the treatment of cutaneous T cell lymphoma.  In 2009, the 
FDA approved another such pan-HDACi, Romidepsin, for the same clinical	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indication [31]. Panobinostat and Entinostat are two newer HDACi’s whose 
clinical development includes trials in patients with advanced stage breast cancer 
[31, 35]. 	  
In addition to pan-HDACi, class-specific HDACi are also in preclinical and 
clinical development.  For example, recent studies have shown that Entinostat, a 
class I HDAC inhibitor, is able to induce apoptosis in breast cancer cells, as well 
as down regulate HER2 and HER3 [35]. In addition, class II specific HDACi’s 
such as MC1568 and MC1575 show anti-proliferative activity in human 
melanoma cells [36], as well as in human breast cancer cells [37].   
This study focuses on a potent pan-HDAC inhibitor, Trichostatin-A (TSA), 
an antifungal antibiotic that acts as a reversible non-competitive inhibitor [38]. 
TSA remains in preclinical studies and has been shown to promote cell cycle 
arrest in the G1 and G2 phases, and in some cases promote apoptosis.  In some 
cancer cells, TSA has been shown to induce differentiation rather than promote 
cell death [38]. TSA (and other pan-HDACi’s) has also been shown to induce 
HER2 mRNA degradation [39]. Furthermore, unpublished data from the Benz lab 
have shown that the addition of cyclohexamide to HER2 positive SKBR3 breast 
cancer cells inhibits polyribosome (polysome) formation and reverses the effects 
of TSA, suggesting that polysome function and active translation appear to be 
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Research Goals 
The focus of this project was to determine the therapeutic potential and 
anti-tumor mechanism of action of mTOR and HDAC inhibitors, represented by 
MLN0128 and TSA respectively, as individual anticancer agents and in 
therapeutic combination, and to determine if their potential utility is dependent on 
a specific breast cancer phenotype, be it hormone receptor (ER, PR)-positive, 
HER2-positive, or neither. Since breast cancer cell lines modeling these different 
breast cancer clinical phenotypes are readily available, we examined the effects 
of these inhibitors on breast cancer cell viability and determined how these 
phenotypically different model breast lines respond to MLN0128/TSA treatment 
given as single agents or in combination. To understand the antitumor 
mechanism(s) of these drugs with regard to phosphorylation events in the 
PI3K/AKT/mTOR signaling pathway, we determined if adding TSA to MLN0128 
impairs or enhances activation of AKT, S6, and/or 4eBP1. Since unpublished 
data from the Benz lab also indicated that polysome function is necessary for 
TSA to induce HER2 mRNA decay, we further evaluated the possibility that 
mTOR inhibition could antagonize the anti-tumor effects of TSA by inhibiting 
polysome function. Furthermore, since HDACi’s can impair cancer cell growth, 
we determined whether its growth inhibiting interaction with MLN0128 induces 
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MATERIALS AND METHODS 
Cell Culture 
Human breast cancer cells lines expressing different levels of ER/PR and 
HER2 levels were cultured under sterile conditions and incubated at 37°C in 5% 
CO2. SKBR3 cells (HER2+/ER-) were grown in McCoy’s medium and 
supplemented with 10% Fetal Bovine Serum (FBS). MDA-MB-231 (ER-/PR-
/HER2-), or triple negative cell line, and JIMT-1 (HER2+/ER-/PR-) Herceptin 
resistant cells, were grown in DMEM and supplemented with 10% FBS. MCF7 
(ER+/PR+/HER2-) cells, and MCF7 HER2-18 (ER+/PR+/HER2+) cell line stably 
overexpressing HER2 45x endogenous levels as described [41] were grown in 
DMEM and supplemented with 10% FBS and 1% insulin. MCF-10A (ER-/PR-
/HER2- ) immortalized but non-tumorigenic mammary epithelial cell line was 
grown in 50% DMEM and 50% Ham’s F12 media supplemented with 5% horse 
serum, 2mmol/L L-glutamine, 0.02 mmol/L non-essential amino acids, 10ng/ml 
EGF, 0.5µg/ml hydrocortisone, 0.1µg/ml cholera toxin, and 10µg/ml of insulin. 
BT-474 (ER+/PR+/HER2+) cell line was grown in RPMI 1640 medium, and 
supplemented with 10% FBS. The JIMT-1 cells were obtained from AddexBio 
(San Diego, CA, USA) all of the other cell lines were originally obtained from the 
(ATCC) American Type Culture Collection (Manassas, VA, USA).  
 
Drugs 
 MLN0128 (INK128) was obtained under a Material Transfer Agreement 
from Intellikine, Inc. (Millennium Pharmaceuticals, Cambridge, MA, USA). TSA 
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and MC1568 were obtained from Sigma Aldrich (St. Louis, MO, USA). Entinostat 
was obtained from Syndax Pharmaceuticals Inc. (Waltham, MA, USA).  
 
Cell Viability Assay  
CellTiter-Glo Cell Viability Assay (Promega, Madison, WI, USA) was used 
to determine cell viability after single agent and combination treatments with 
TSA, MLN0128, Entinostat and MC1568 according to manufacturer’s protocol. 
SKBR3 and BT-474 breast cancer cell lines were plated at 5000 cells/well, and 
MCF7 NEO3, MCF7 HER2-18, MCF-10A, MDA-MB-231, and JIMT-1 cells were 
plated at 2500 cells/well in a 96 well plate. (Equal confluences of each cell line 
were obtained). After a 24-hour period where the cells were allowed to attach, 
the cells were treated with DMSO (as a positive control) 0nM, 25nM, 50nM, and 
100nM concentration of TSA and 0nM, 0.2nM, 1nM, 5nM, and 25nM 
concentration of MLN0128 for 72 hours. Control cells were treated by vehicle 
used to dissolve each drug. To determine the growth inhibitory effects of TSA, 
Entinostat, and MC1568, SKBR3 cells were plated in a 96 well plate at 5000 
cells/well. Cells were allowed to attach for 24 hours and then treated with DMSO, 
0nM, 125nM, 250nM, 500nM, and 1000nM of each drug for 72 hours. Cell 
viability was quantified using a Fluoroskan luminometer (Ascent, FL). IC50 values 
for MLN0128 and TSA were calculated using GraphPad Prism version 5.0. 
Synergism interactions were analyzed using Calcusyn Software (Biosoft, Great 
Shelford Cambridge, UK).  
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Western Blot Analysis 
SKBR3 and BT-474 cells were plated at approximately 5.5 x 105 cells/well, 
and MCF7 NEO3, MCF7 HER2-18, MCF-10A, and JIMT-1 cells were plated at 
approximately 2.5 x 105 cells/well in a 6-well plate. The cells were allowed to 
attach for 24 hours, and were treated with the DMSO, 0nM, 25nM, 50nM, and 
100nM concentration of TSA and 0nM, 0.2nM, 1nM, 5nM, and 25nM 
concentration of MLN0128 for 8 hours. Whole cell lysates were washed with 
Phosphate-Buffered Saline (PBS) and harvested in RIPA buffer (10 mM Tris-CL 
(pH 8.0), 1mM EDTA, 0.5 mM EGTA, 1% triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, 140 mM NaCl) containing complete Mini, EDTA-free 
Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor Cocktail 
tablets, (Roche, Indianapolis, IN, USA). Cell lysates were then centrifuged at 
14,000rpm, pellets discarded, and supernatants were stored in -80°C.  
Protein concentration was determined using the Bradford Coomassie 
Assay (BCA) kit (Pierce, Rockford, IL, USA). Protein concentrations among the 
samples were normalized by the addition of appropriate amounts of RIPA buffer, 
After the addition of 2X SDS sample buffer, samples were separated by SDS-
PAGE gel electrophoresis using NuPAGE 4-12% Bis-Tris-Gel (Life Technologies, 
Grand Island, NY, USA). Proteins were transferred onto a PVDF membrane 
(COMPANY), and membrane was blocked for 1 hour in 4% nonfat dried milk in 
1X TBST (Tris buffered saline with 0.05% Tween 20 pH 8.0 (Sigma Aldrich, St. 
Louis, MO, USA)). Western blot analysis was performed using protein-specific 
antibodies: pS6 S240/244 rabbit monoclonal antibody (mAb), p4eBp1 S65 rabbit 
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mAb, 4eBp1 rabbit mAb, pAKT-S473 rabbit mAb, AKT rabbit polyclonal antibody, 
Beta-tubulin rabbit polyclonal antibody, pS6 rabbit mAb, S6 rabbit mAb, and 
Cleaved PARP rabbit mAb (Cell Signaling, Danvers, MA, USA). Mouse 
monoclonal HER2 antibody was obtained from Cal Biochem (now Millipore, 
Billerica, MA, USA) and rabbit polyclonal pHER2 antibody was obtained from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The antibodies were 
detected using secondary antibodies conjugated to horse radish peroxidase and 
luminol as a substrate (Thermo Fisher Scientific, Rockford, IL, USA).  
 
Polysome Fractionation 
SKBR3 cells were plated at approximately 1.2 x 107 cells per 15cm plate, 
and were allowed to attach for 24 hours. Cells were treated with the DMSO (as a 
positive control), 0nM, and 50nM of MLN0128, and 0nM, and 500nM 
concentrations of TSA, in single agent and combination for 24 hours. Cells were 
then treated with 50µg/ml cyclohexamide for 15min to immobilize ribosome 
complexes. After removing media and washing harvested cells with (Dulbecco’s 
Phosphate-Buffered Saline (DPBS), SKBR3 cells were scraped and transferred 
to dounce homogenizer on ice, and homogenized with lysis buffer (0.1M sodium 
orthovanadate, protease inhibitor, phosphatase inhibitor, 50µg/ml cyclohexamide, 
RNAse inhibitor, and NP-40 buffer). The samples were spun at 14,000rpm for 5 
minutes, and pellet was discarded. The samples were snap frozen in liquid 
nitrogen, and stored in the -80°C until day of polysome fractionation.   
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Polysome profile analysis was employed as recently described [40]. A 
sucrose gradient was poured by layering 10%-50% sucrose buffers. Gradients 
were kept at room temperature for 1hr and 45 minutes to form continuous 
gradient, and placed in the -80°C until the day of polysome fractionation. On the 
day of fractionation, the samples were layered on top of the continuous sucrose 
gradient and the samples were spun at 38,000 rpm for 2 hours at 4°C. The 
gradients were fractioned and polysome fractions were then collected by utilizing 
the Retriever 500 with ISCO Teledyne UV/Vis (UA6).  
 
Apoptosis Assay 
SKBR3 cells were plated at approximately 4 x105 cells/well in a 6 well 
plate. Twenty-four hours later, cells were treated with 0nM and 100nM 
concentration of TSA, and 0nM and 25nM concentration of MLN0128. SKBR3 
cells treated with 5µg/mL Adriamycin served as a positive control for apoptotic 
cells. Whole cells lysates were prepared by the same methods stated above and 
Western blot analysis was used to analyze PARP cleavage using anti-PARP 
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RESULTS 
 
Combination of TORC1/2 and pan-HDAC inhibitors synergistically 
decreases breast cancer cell viability 
To assess the effect of single agent and combination treatment using the 
TORC1/2 inhibitor, MLN0128, and the pan-HDACi TSA, we utilized the CellTiter-
Glo assay to measure cell viability in a variety of breast cancer cells (Figure 2). 
IC50 values for MLN0128 and TSA ranged from 4.64nM to 25nM, and 30.9nM 
to100nM, respectively (Figure 3). Among all the cell lines tested, SKBR3 cells 
appeared to be the most sensitive to single agent and dual treatment with both 
drugs (Figure 2A). The IC50 for MLN0128 in SKBR3 cells was 4.64nM, and 
30.9nM for TSA (Figure 3). MCF7 NEO3 cells were also sensitive to treatment 
with MLN0128 and TSA, with IC50 values of 14.1nM for MNLO128, and 63.1nM 
for TSA (Figure 2B, and 3). The most resistant cell lines were the MCF7 HER2-
18, BT-474, JIMT-1, and MCF-10A (Figure 2C, 2D, 2E, 2G). These cell lines had 
IC50 values ranging from 14.1nM to 25nM for MLN0128, and 63.1nM to 100nM 
for TSA (Figure 3). MDA-MB-231 cells were more sensitive to MLN0128 with an 
IC50 value of 11.75nM, but less affected by TSA with an IC50 value of 89.13nM 
(Figure 2F and 3). The non-malignant mammary epithelial cells, MCF-10A were 
the most resistant, and had IC50 values of 25.1nM and 100nM for MLN0128 and 
TSA, respectively (Figure 2G, and 3). There were no correlations observed with 
regard to known breast cancer phenotype or genotype, including ER and HER2 
status or PI3K mutation status (Figure 3).  
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In order to determine if additive, synergistic, or antagonistic interactions 
exist between MLN0128 and TSA, we used Calcusyn software to calculate the 
combination index (CI) (Figure 4). A combination index of 1 indicates that two 
drugs are acting in an additive manner.  CI values less than 1 represent 
synergism while values greater than 1 represent antagonism.  CI was calculated 
for the cells that were sensitive enough to MLN0128 and TSA and we found that 
the overall effects of combining MLN0128 and TSA showed synergistic 
interaction with CI values ranging from 0.264-0.898 (Figure 4). The MDA-MB-231 
cells appeared to show an antagonistic effect at low doses of MLN0128 and TSA 
(25nM and 50nM), however higher doses (25nM and 100nM) of both drugs 
showed the strongest synergistic interaction, with a CI of 0.264, compared with 
all other cell lines tested (Figure 4). Furthermore, nearly additive effects were 
observed in the MCF7 HER2-18 cells, at the 25nM MLN0128 and 50nM TSA 
dose with a CI value of 0.903 (Figure 4).  These results show that combination of 
MLN0128 and TSA synergistically inhibit breast cancer cell viability compared 
with single agent treatment using either drug alone.   
 
TORC1/2 inhibitor blocks downstream signaling effectors 
To examine the early effects of MLN0128 and TSA on the 
PI3K/AKT/mTOR pathway, various breast cancer cell lines were treated for 8-
hours with concentrations similar to the ones used in the viability assays (Figure 
5). MLN0128 alone reduced phosphorylation levels of S6 and 4eBP1 in all cell 
lines. While single agent treatment of TSA did not have an effect on the 
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phosphorylation of S6 or 4eBP1, the combination of MLN0128 and TSA showed 
a reduced phosphorylation of 4eBP1 in SKBR3, MCF7 HER2-18, and MCF-10A 
cells compared to single agent treatments of either drug (Figure 5A, 5C, and, 
5F). As expected, MLN0128 treatment reduced AKT S473 phosphorylation in all 
cell lines tested and TSA alone reduced AKT phosphorylation in the cell lines 
most responsive to TSA treatment: SKBR3, MCF7 NEO3, MCF7 HER2-18 
(Figure 5A, 5B, 5C). In addition, phosphorylation of AKT on S473 was further 
reduced with dual MLN0128/TSA treatment as compared to the single agent 
treatments in all cell lines tested (Figure 5).  Even in cell lines where TSA 
treatment alone did not affect AKT phosphorylation (BT-474, JIMT-1, MCF-10A), 
adding TSA at 100nM further decrease AKT phosphorylation (Figure 5D, 5E, 5F). 
To determine the effects of long-term treatment with MLN0128 and/or TSA 
on PI3K/mTOR/AKT pathway signaling events, we evaluated 24-hour treatments 
of both drugs as single agents, or in combination at varying concentrations of 
TSA (0nM, 50nM, and 1000nM) (Figure 6). Although low doses of MLN0128 
decreased the phosphorylation of S6 and 4eBP1, very high doses of TSA 
(1000nM) were necessary to block S6 and 4eBP1 phosphorylation.  Furthermore, 
high doses of TSA in combination with MLN0128 further inhibited S6 and 4eBP1 
phosphorylation when compared to either of the single agent treatments (Figure 
6), suggesting that both drugs are capable of modulating S6 and 4eBP1 
phosphorylation with MLN0128 being more potent than TSA. 
As previously mentioned, unpublished Benz Lab data shows that TSA 
promotes HER2 mRNA degradation in a polysome dependent manner. Since 
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MLN0128 affects the phosphorylation of ribosomal proteins, including S6 (Figure 
5), we next examined whether MLN0128 can prevent TSA-mediated reduction in 
HER2 levels. Results in figure 7 indicate that HER2 protein levels were 
decreased following a 24-hour treatment with 1000nM of TSA even in the 
presence of MLN0128 (Figure 7). While TSA did not alter HER2 protein levels 
significantly within 24 hours of treatment, it did reduce pHER2 to a non-
detectable level and blocked HER2 activation. MLN0128 did not appear to have 
any effect on HER2 activation or total HER2 levels in absence of TSA, nor did it 
appear to interfere with the effects of TSA on HER2 expression or 
phosphorylation (Figure 7). The observed decrease in HER2 protein levels may 
be attributed to mRNA degradation; further testing will be necessary to examine 
the effects of TSA and MLN0128 on HER2 mRNA levels.  
 
Inhibitors of TORC1/2 and HDACs decrease polysome formation 
 The PI3K/AKT/mTOR pathway is known to affect posttranslational 
modifications on ribosomal proteins and translation initiation factors [28], Since 
sustained TSA reduced S6 phosphorylation after 24 hours of treatment (Figure 6) 
we investigated the effects of MLN0128 and TSA on polysome formation and 
structure. We used a 50nM concentration of MLN0128 (10x the IC50 value) and a 
500nM of TSA (16x the IC50 value).  MLN0128 alone caused a subtle decrease in 
polysome formation, as did TSA as single agents. The combination of MLN0128 
and TSA significantly blocked polysome formation, greater than either of the 
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drugs alone (Figure 8). These results support the convergent influence of 
MLN0128 and TSA in decreasing polysome formation, at least in SKBR3 cells.   
 
Combined treatment with TORC1/2 and HDAC inhibitors induces apoptosis 
in breast cancer cells 
MLN0128 and TSA have been shown to lower the viability of breast 
cancer cells and, and to a lesser extent, non-transformed mammary epithelial 
cells (Figure 2).  We investigated whether this difference in viability is related to 
increased apoptosis in SKBR3 cells in response to MLN0128 and/or TSA. To 
accomplish this, we examined PARP cleavage as a marker for apoptosis in 
SKBR3 (HER2+/ER-) cells and non-transformed MCF-10A mammary epithelial 
cells. Cells were treated for 48 hours with 25nM of MLN0128 and 100nM of TSA 
(highest concentrations used in the viability experiments) alone or in 
combination, with adriamycin treated cells used as a positive control for PARP 
cleavage (Figure 9).  In SKBR3 cells, MLN0128 or TSA alone caused only a 
small increase in cleaved PARP levels, however, this cleavage was further 
enhanced when the two drugs were given in combination (Figure 9). No PARP 
cleavage was observed in the MCF-10A cells, with any of the MLN0128 and/or 
TSA treatment doses (Figure 9). Taken together, our results show that MLN0128 
and TSA alone or in combination inhibit SKBR3 breast cancer cell growth by 
promoting apoptosis, whereas these drugs appear to have little effect on non-
transformed MCF-10A cells.  
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Class I HDACi showed greater reduction in breast cancer cell viability 
compared to class II HDACi.  
 In order to determine whether the growth inhibitory effects of HDAC 
inhibitors are class I or class II dependent, we treated SKBR3 cells with 
Entinostat (class I HDACi), and MC1568 (class II HDACi), as well as TSA (pan-
HDACi) (Figure 10). Cells were treated with the aforementioned drugs for 72 
hours and a cell viability assay was performed as before. Results in figure 10 
indicate that TSA is more potent in inhibiting cell viability in comparison to the 
other two HDACi’s. While Entinostat displayed growth inhibitory effects at higher 
dosages, MC1568 did not appear to have any inhibitory effects, even at the 
highest concentration of 1000nM (Figure 10). However further research with 
other class I and class II specific HDACi’s are necessary to have a better 
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DISCUSSION 
           HER2 overexpression and phosphorylation, and the activation of the 
PI3K/Akt/mTOR pathway have been linked to increased breast cancer cell 
survival, growth, and metastasis [7, 16, 17]. HER2 amplification has been 
associated with very poor prognosis in breast cancer patients [7] with a variety of 
resistance mechanisms developing either de novo or soon after clinical treatment 
with HER2 targeted therapies. In this study, we tested the therapeutic potential of 
a potent and investigational mTORC1/2 inhibitor, MLN0128, as a stand-alone 
treatment and in combination with a pan-HDAC inhibitor, TSA.  Studies were 
conducted to evaluate the effects of these drugs alone or in combination on cell 
viability, PI3K/Akt/mTOR signaling, and polysome formation.  
Our data show that MLN0128 and TSA synergistically inhibit cell viability 
when administered in combination (Figure 2). While both drugs were effective in 
blocking cell viability in a dose-dependent manner against a panel of 
phenotypically diverse breast cancer cell lines, we did not observe any patterns 
of responsiveness that correlated with a specific breast cancer clinical (i.e. HER2 
or ER receptor) phenotype (Figure 3). Interestingly, MLN0128 and TSA as single 
or combination treatments, appeared to have little effect on non-malignant 
mammary epithelial cells, MCF-10A (Figure 2G).  These results suggest that 
MLN0128 and TSA given in combination could exhibit antitumor activity in vivo 
without significant toxicity to non-malignant cells; however, this conclusion 
requires additional preclinical in vivo testing.  
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In addition to inhibiting cell viability, studies have shown that MLN0128 is 
effective in blocking mTORC1/2 signaling which promotes survival of cancer cells 
by regulating proliferation, growth, metabolism, invasiveness, and motility [22]. 
More specifically, MLN0128 has been reported to inhibit pS6, p4eBP1, and 
pAKT-S473, in preclinical studies [27-30]. In line with these studies, our results 
also indicate that MLN0128 inhibits phosphorylation of S6 and 4eBP1 (Figure 5), 
both of which are downstream effector molecules of mTOR [23, 25]. 
Furthermore, earlier studies have indicated that inhibition of mTORC1 alone may 
not be sufficient because mTORC1 inhibitors (rapalogs) have been shown to 
increase the phosphorylation of AKT on S473 [23, 29]. Consistent with this, data 
from this study also show that MLN0128 is able to inhibit AKT S473 
phosphorylation. We also demonstrated that TSA in combination with MLN0128 
further reduces the phosphorylation of AKT S473, even though, in most cell lines 
tested, TSA alone has little if any effect on pAKT-S473 after 8 hours of treatment 
(Figure 5). Although TSA was not able to inhibit pS6 and p4eBP1 after 8 hours of 
treatment, at a longer time point and higher doses, TSA did reduce 
phosphorylation levels of S6 and 4eBP1 when used in combination with 
MLN0128 (Figure 6). Taken together, these findings suggest that pS6 and 
p4eBP1 could serve as robust biomarkers for MLN0128 response, and that 
pAKT-S473 may serve as a response biomarker for the MLN0128 and TSA 
combination therapy.   
Since polysome function contributes to HER2 protein expression and is 
necessary for TSA to induce HER2 mRNA decay, we examined the effects of 
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MLN0128 and TSA on polysome formation. Similar to the cell viability results, the 
combination treatment of MLN0128 and TSA at concentrations above their IC50 
values was more effective at decreasing polysome formation than the individual 
drugs alone (Figure 8).  
The results of our viability studies indicate that MLN0128 and TSA 
synergistically inhibit viability of a variety of breast cancer cells lines, and to a 
lesser degree, non-transformed mammary epithelial cells. We found that, in 
SKBR3 cells, that reduction in viability is caused, at least in part, by induction of 
apoptosis; as single agents, both MLN0128 and TSA increased PARP cleavage, 
while the combination treatment showed an even stronger effect on this apoptotic 
marker (Figure 9). In contrast, the non-transformed MCF-10A cells did not show 
any significant induction of apoptosis, which underscores the potential clinical 
use of these two drugs in combination. 
Since TSA is a pan HDACi that targets both class I and class II HDAC’s, 
we investigated whether the reduction in cell viability is dependent on class I 
HDACs, class II HDAC’s, or on both classes. We found that treatment with one 
specific class I HDACi caused greater reduction in cell growth in comparison with 
the treatment of a different class II HDACi (Figure 10), implicating the greater 
contribution of class I HDACs in regulating breast cancer cell growth and 
potentially accounting for the observed synergy with MLN0128. However, further 
evaluation with additional class-specific HDACi’s is necessary to firmly establish 
this conclusion. 
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Further research to better understand the interaction between TORC1/C2 
inhibition and HDAC inhibition as a new therapeutic strategy are necessary. It will 
be interesting to examine if MLN0128 affects canonical TSA-induced events, 
such as increased p21 levels [31]. More importantly, although we examined 
class-selective HDACi, it will be critical to determine if the synergistic growth 
inhibiting effects induced by the combination treatment depend mostly on TSA 
inhibition of class I, class II or both classes of intracellular HDACs. Also, the 
finding that MLN0128 and TSA induced-apoptosis is observed in SKBR3 cells, 
but not in the non-transformed MCF-10A’s, leads us to wonder if the drugs can 
induce senescence in MCF10A cells. Such additional studies will enhance the 
preclinical rationale to warrant further development of targeted therapy focused 
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CONCLUSION 
Our data indicate that the combination of an mTORC1/C2 inhibitor like 
MLN0128 and a pan-HDACi like TSA is more effective at inhibiting cell viability, 
polysome function, and AKT phosphorylation, and inducing apoptosis, than 
single agent treatment by either drug alone. In addition to the aforementioned 
convergent mechanisms of action, both MLN0128 and TSA display drug-specific 
molecular events; for example, MLN0128 is more robust in reducing S6 and 
4eBP1 phosphorylation, while TSA, but not MLN0128, reduces HER2 activation 
and receptor levels. Taken together, the results from this study demonstrate that 
both drugs inhibit cell growth and promote apoptosis in various breast cancer cell 
lines through both convergent (i.e. both drugs decrease AKT phosphorylation) 
and divergent pathways (MLN0128 is a much more potent inhibitor of S6 and 
4eBP1 phosphorylation compared to TSA). Further research with this innovative 
therapeutic drug combination may lead to the development of more effective 
anticancer treatment regimens, especially for HER2-positive breast cancers 
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Figure 1. Schematic of signaling pathways targeted by MLN0128 and TSA. HER2 (and other RTK’s)  
dimerization and auto-phosphorylation leads to PI3K/AKT/mTOR activation and subsequently the phosphorylation of 
downstream targets of mTOR. Phosphorylation of S6K and 4eBP1 results in increased cell proliferation and metastasis. 
mTOR inhibitor MLN0128 (INK128) blocks both TORC1 and TORC2 to inhibit the functions of both S6K and 4eBP1. 
Inhibition of TORC2 by MLN0128 decreases Akt activity and prevents IRS-1 from further up-regulating AKT after 
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Figure 2. MLN0128 and TSA synergistically inhibit breast cancer cell viability to different degrees in a     
           phenotypically diverse set of breast cancer cell lines. A.SKBR3 cells B. MCF7 NEO3 C. MCF7 HER2-18  
           D. BT-474 E. JIMT-1 F. MDA-MB-231 G. MCF-10A. All cell lines were treated with same increasing concentrations 
           of TSA and MLN0128, in single agent or combination treatments for 3 days. Cell viability assay was performed. 
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    Figure 3. MLN0128 and TSA reduce the viability of a phenotypically diverse panel of breast cancer cell lines 
      with non-transformed MCF10A breast epithelial cells being less affected. IC50 values were calculated for   
      MLN0128 and TSA from each cell line listed following a 3-day cell viability assay.  
 
 
   Figure 4. MLN0128 and TSA inhibit breast cancer cell viability in a synergistic manner. Combination index (CI) 
   was calculated in all cell lines where a sufficient effect on viability was observed using the Calcusyn software.   
   Antagonism is indicated by a CI >1.10. Additivity is indicated by a CI ranging from 0.90-1.10, and synergism is 
   indicated by a CI ranging from 0.1-0.90. [43]. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  





      










	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  


















	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  









Figure 5. MLN0128 and TSA decrease phosphorylation of downstream effector molecules of mTOR. A. SKBR3 B. 
MCF7 NE03 C. MCF7 HER2-18 D. BT-474 E. JIMT-1 F. MCF-10A. Cells were treated with MLN0128 and TSA for 8 
hours. Whole cell lysates were collected and western blots were performed using protein specific antibodies. 
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        Figure 6. MLN0128 and high doses of TSA reduces pS6 and p4eBP1 levels after 24 hours of treatment.  
        SKBR3 cells were treated with MLN0128 and TSA with increasing concentrations of both drugs as single agents  




      Figure 7. TSA reduces pHER2 and total HER2 protein levels. SKBR3 cells were treated  
      and analyzed as in Figure 6. Beta tubulin was used as a loading control.  
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       Figure 8. Combination of MLN0128 and TSA decreases polysome formation. SKBR3 cells were treated 






   Figure 9. Dual treatment with MLN0128 and TSA induces apoptosis in SKBR3 cells.  SKBR3 and MCF-10A cells 
   were treated with MLN0128 and TSA for 48 hours with adriamycin treated cells as a positive control. Whole cell lysates  
   were collected for western blot analysis to probe for cleaved PARP as a marker for apoptosis.  
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         Figure 10.  Class I HDAC inhibitor showed greater reduction in breast cancer cell viability compared to 
         class II HDAC inhibitor. SKBR3 cells were treated with TSA, Entinostat, or MC1568 for 3 days. Cell viability assay  
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